{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:43:48Z","timestamp":1786113828525,"version":"build-2736575974"},"reference-count":102,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.arcmed.2026.103476","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:03:43Z","timestamp":1783591423000},"page":"103476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Addressing the Public Health Threat of Steatotic Liver Disease in Mexico"],"prefix":"10.1016","volume":"57","author":[{"given":"Mar\u00eda Fernanda","family":"Bautista Gar\u00edn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sim\u00f3n","family":"Barquera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela Elia","family":"Castro-Narro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid Ruiz","family":"Margain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo U.","family":"Mac\u00edas-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leire","family":"Agirre-Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Arellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Ram\u00edrez-Butanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9618-2299","authenticated-orcid":false,"given":"Jeffrey V","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2026.103476_bib0001","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults","volume":"11","author":"Huang","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.arcmed.2026.103476_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"2024","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0003","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra2412865","article-title":"Metabolic Dysfunction\u2013Associated Steatotic Liver Disease","volume":"393","author":"Targher","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2026.103476_bib0004","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0005","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic Dysfunction\u2013Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.arcmed.2026.103476_bib0006","doi-asserted-by":"crossref","first-page":"5","DOI":"10.17925\/EE.2024.20.2.2","article-title":"Metabolic Dysfunction-associated Steatotic Liver Disease and Type 2 Diabetes: A Deadly Synergy","volume":"20","author":"Leith","year":"2024","journal-title":"touchREV Endocrinol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0007","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1038\/s41591-025-03759-8","article-title":"The People-First Liver Charter","volume":"31","author":"Lazarus","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.arcmed.2026.103476_bib0008","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis","volume":"72","author":"En Li Cho","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.arcmed.2026.103476_bib0009","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jhep.2021.10.025","article-title":"The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?","volume":"76","author":"Lazarus","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0010","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/HEP.0000000000000545","article-title":"A global action agenda for turning the tide on fatty liver disease","volume":"79","author":"Lazarus","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.arcmed.2026.103476_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2025.102171","article-title":"Name MASLD\/MASH - and act on it","volume":"31","author":"Lazarus","year":"2026","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0012","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/HEP.0000000000000361","article-title":"The global fatty liver disease Sustainable Development Goal country score for 195 countries and territories","volume":"78","author":"Lazarus","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.arcmed.2026.103476_bib0013","unstructured":"World Health Organization (WHO). Political declaration of the fourth high-level meeting of the General Assembly on the prevention and control of noncommunicable diseases and the promotion of mental health and well-being. New York; 2025 Dec. Available from: https:\/\/www.who.int\/publications\/m\/item\/political-declaration-of-the-fourth-high-level-meeting-of-the-general-assembly-on-the-prevention-and-control-of-noncommunicable-diseases-and-the-promotion-of-mental-health-and-well-being. (Accessed March 23, 2026)."},{"key":"10.1016\/j.arcmed.2026.103476_bib0017","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/S0140-6736(23)00013-2","article-title":"Defining and conceptualising the commercial determinants of health","volume":"401","author":"Gilmore","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2026.103476_bib0019","unstructured":"IDF Diabetes Atlas. 2025. Report No.: 11th edition. Available from: https:\/\/diabetesatlas.org\/media\/uploads\/sites\/3\/2025\/04\/IDF_Atlas_11th_Edition_2025.pdf. (Accessed March 23, 2026)."},{"key":"10.1016\/j.arcmed.2026.103476_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2025.102149","article-title":"Assessment of metabolic dysfunction-associated steatotic liver disease, alcohol-associated liver disease, and metabolic dysfunction and alcohol-associated steatotic liver disease in open Mexican population","volume":"31","author":"Lira-Vera","year":"2026","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0021","first-page":"199","article-title":"Prevalence and clinical-epidemiologic characteristics of a Mexican population with metabolic (dysfunction) associated fatty liver disease: An open population study","volume":"88","author":"Bernal-Reyes","year":"2023","journal-title":"Rev Gastroenterol Mex (Engl Ed)"},{"key":"10.1016\/j.arcmed.2026.103476_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101175","article-title":"The burden of liver disease in Latin America","volume":"29","author":"D\u00edaz","year":"2024","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0023","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.arcmed.2026.103476_bib0024","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/hep.24283","article-title":"Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease","volume":"53","author":"Sookoian","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.arcmed.2026.103476_bib0025","article-title":"Instituto Nacional de Estad\u00edstica y Geograf\u00eda. Estad\u00edstica de Defunciones Registradas (EDR), enero\u2013junio 2025. Resultados preliminares. M\u00e9xico: INEGI","year":"2025","journal-title":";"},{"key":"10.1016\/j.arcmed.2026.103476_bib0026","unstructured":"Institute for Health Metrics and Evaluation (IHME). GBD Results, IHME, University of Washington. Available from: https:\/\/vizhub.healthdata.org\/gbd-results\/. (Accessed March 17, 2026)."},{"key":"10.1016\/j.arcmed.2026.103476_bib0027","first-page":"153","article-title":"Transicionando de NAFLD a MAFLD y a MASLD en la poblaci\u00f3n mexicana","volume":"90","author":"Priego-Parra","year":"2025","journal-title":"Rev Gastroenterol M\u00e9x"},{"key":"10.1016\/j.arcmed.2026.103476_bib0028","first-page":"637","article-title":"Adjusted prevalence of metabolic-associated steatotic liver disease (MASLD) in a Mexican","volume":"90","author":"Bernal-Reyes","year":"2025","journal-title":"Rev Gastroenterol Mex (Engl Ed)"},{"key":"10.1016\/j.arcmed.2026.103476_bib0029","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.gastha.2021.12.011","article-title":"Prevalence of Metabolic-associated Fatty Liver Disease in Mexico and Development of a Screening Tool: The MAFLD-S Score","volume":"1","author":"Ruiz-Manriquez","year":"2022","journal-title":"Gastro Hep Adv"},{"key":"10.1016\/j.arcmed.2026.103476_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2025.103240","article-title":"Changing Landscape of Liver Cirrhosis Etiologies","volume":"56","author":"M\u00e9ndez-S\u00e1nchez","year":"2025","journal-title":"Arch Med Res"},{"key":"10.1016\/j.arcmed.2026.103476_bib0031","article-title":"Situational panorama of chronic liver diseases: A single-center experience at a university hospital in northeast Mexico (1995-2019)","volume":"31","author":"Cordero-Perez","year":"2025","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100876","article-title":"Changing epidemiology of hepatocellular carcinoma in South America: A report from the South American liver research network","volume":"28","author":"Farah","year":"2023","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0033","doi-asserted-by":"crossref","DOI":"10.24875\/GMM.M24000827","article-title":"Burden of disease due to liver cirrhosis in Mexico","volume":"159","author":"Flores-Garc\u00eda","year":"2024","journal-title":"GMM"},{"key":"10.1016\/j.arcmed.2026.103476_bib0034","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.cgh.2025.02.035","article-title":"Novel Noninvasive Tests for Liver Fibrosis: Moving Beyond Simple Tests in Metabolic Dysfunction-associated Steatotic Liver Disease","volume":"24","author":"Grady","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0035","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/HEP.0000000000000843","article-title":"AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.arcmed.2026.103476_bib0036","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/MEG.0000000000002741","article-title":"Prevalence, trends, and characteristics of metabolic dysfunction-associated steatotic liver disease among the US population aged 12\u201379 years","volume":"36","author":"Shen","year":"2024","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0037","article-title":"Relationship between MASLD and women\u2019s health: A review","volume":"21","author":"Jancova","year":"2025","journal-title":"Womens Health (Lond)"},{"key":"10.1016\/j.arcmed.2026.103476_bib0038","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.3390\/biomedicines13092292","article-title":"Sex Differences in MASLD After Age 50: Presentation, Diagnosis, and Clinical Implications","volume":"13","author":"Milani","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.arcmed.2026.103476_bib0039","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0040","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/apt.70433","article-title":"Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction\u2013Associated Steatotic Liver Disease","volume":"63","author":"Tesfai","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.arcmed.2026.103476_bib0041","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph191912221","article-title":"Impact on Prevalence of the Application of NAFLD\/MAFLD Criteria in Overweight and Normal Weight Patients","volume":"19","author":"Ordo\u00f1ez-V\u00e1zquez","year":"2022","journal-title":"IJERPH"},{"key":"10.1016\/j.arcmed.2026.103476_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2024.102495","article-title":"Global Epidemiology and Implications of PNPLA3 I148M Variant in Metabolic Dysfunction\u2013Associated Steatotic Liver Disease: A Systematic Review and Meta-analysis","volume":"15","author":"Souza","year":"2025","journal-title":"J. Clin. Exp. Hepatol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0043","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0044","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s11033-016-4058-z","article-title":"Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight\/obese Mexican adults","volume":"43","author":"Flores","year":"2016","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.arcmed.2026.103476_bib0045","doi-asserted-by":"crossref","first-page":"250","DOI":"10.5604\/01.3001.0010.8644","article-title":"More Evidence for the Genetic Susceptibility of Mexican Population to Nonalcoholic Fatty Liver Disease through PNPLA3","volume":"17","author":"Chinchilla-L\u00f3pez","year":"2018","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0046","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.yexmp.2015.01.012","article-title":"A genetic risk score is associated with hepatic triglyceride content and non-alcoholic steatohepatitis in Mexicans with morbid obesity","volume":"98","author":"Le\u00f3n-Mimila","year":"2015","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0047","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1007\/s11033-014-3341-0","article-title":"PNPLA3 I148M polymorphism is associated with elevated alanine transaminase levels in Mexican Indigenous and Mestizo populations","volume":"41","author":"Larrieta-Carrasco","year":"2014","journal-title":"Mol Biol Rep"},{"issue":"394","key":"10.1016\/j.arcmed.2026.103476_bib0048","first-page":"1231","article-title":"Consortium of the Center to End Corporate Harm, University of California, San Francisco. Corporate Vectors of Chronic Disease \u2014 Using Internal Industry Documents to Craft Counterstrategies","volume":"26","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2026.103476_bib0049","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41575-024-00959-4","article-title":"Food inequity and insecurity and MASLD: burden, challenges, and interventions","volume":"21","author":"Zelber-Sagi","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0050","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jhep.2024.08.011","article-title":"Association of food insecurity with MASLD prevalence and liver-related mortality","volume":"82","author":"Younossi","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0051","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000792","article-title":"The impact of food insecurity on chronic liver disease: A systematic review of the literature","volume":"9","author":"Elias","year":"2025","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.arcmed.2026.103476_bib0052","doi-asserted-by":"crossref","DOI":"10.1111\/ijpo.13109","article-title":"Food insecurity is a risk factor for metabolic dysfunction-associated steatotic liver disease in Latinx children","volume":"19","author":"Maxwell","year":"2024","journal-title":"Pediatr Obes"},{"key":"10.1016\/j.arcmed.2026.103476_bib0053","doi-asserted-by":"crossref","first-page":"30","DOI":"10.14309\/ajg.0000000000002572","article-title":"ACG Clinical Guideline: Alcohol-Associated Liver Disease","volume":"119","author":"Jophlin","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0054","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/add.15204","article-title":"Alcohol use disorder and the liver","volume":"116","author":"Buchanan","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.arcmed.2026.103476_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.healthplace.2026.103652","article-title":"Understanding rural food environments and malnutrition-related mortality disparities: A typological approach from Mexico","volume":"99","author":"Jim\u00e9nez-Ortega","year":"2026","journal-title":"Health Place"},{"key":"10.1016\/j.arcmed.2026.103476_bib0056","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1016\/S0140-6736(25)01566-1","article-title":"Policies to halt and reverse the rise in ultra-processed food production, marketing, and consumption","volume":"406","author":"Scrinis","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2026.103476_bib0057","unstructured":"World Health Organization. Guideline: Sugars intake for adults and children. Geneva, Switzerland: World Health Organization; 2015. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241549028. (Accessed March 23, 2026)."},{"key":"10.1016\/j.arcmed.2026.103476_bib0058","article-title":"Quick buys for prevention and control of noncommunicable diseases","volume":"52","author":"Galea","year":"2025","journal-title":"Lancet Regl Health Eur"},{"key":"10.1016\/j.arcmed.2026.103476_bib0059","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2352-4642(25)00242-1","article-title":"Mexico\u2019s school junk food ban to foster healthier futures","volume":"9","author":"Balakrishnan","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.arcmed.2026.103476_bib0060","article-title":"Cuando la industria pesa sobre el est\u00f3mago","author":"Vigna","year":"2025","journal-title":"Instituto Nacional de Salud P\u00fablica (INSP)"},{"issue":"17","key":"10.1016\/j.arcmed.2026.103476_bib0061","doi-asserted-by":"crossref","first-page":"8959","DOI":"10.3390\/ijerph17238959","article-title":"Health-Related Factors in Rural and Urban Mexican Adolescents from the State of Jalisco: The HELENA-MEX Study","volume":"2","author":"Rivera-Ochoa","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.arcmed.2026.103476_bib0062","article-title":"Alcohol-related liver disease: A global perspective","volume":"29","author":"Castro-Narro","year":"2024","journal-title":"Ann Hepatol"},{"issue":"26","key":"10.1016\/j.arcmed.2026.103476_bib0063","article-title":"Episodic Heavy Drinking and Implications for Steatotic Liver Disease Nomenclature: A National Cross-Sectional Study","volume":"S1542-3565","author":"Su","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2025.105014","article-title":"The impact of alcohol minimum pricing policies on vulnerable populations and health equity: A rapid review","volume":"145","author":"Clay","year":"2025","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.arcmed.2026.103476_bib0066","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jhep.2023.11.006","article-title":"Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes","volume":"80","author":"D\u00edaz","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0067","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41575-025-01084-6","article-title":"Public health policies to prevent alcohol-related liver disease","volume":"22","author":"Parker","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0068","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2026.01.026","article-title":"Alcohol Industry Influence on Public View and Policymaking: Implications for Liver Health","author":"Manuli","year":"2026","journal-title":"Gastroenterol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0069","doi-asserted-by":"crossref","unstructured":"OECD. Preventing Harmful Alcohol Use. OECD Publishing; 2021. (OECD Health Policy Studies). Available from: https:\/\/www.oecd.org\/en\/publications\/preventing-harmful-alcohol-use_6e4b4ffb-en.html. https:\/\/doi.org\/10.1787\/6e4b4ffb-en. (Accessed April 6, 2026).","DOI":"10.1787\/6e4b4ffb-en"},{"key":"10.1016\/j.arcmed.2026.103476_bib0070","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.aohep.2020.09.006","article-title":"Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease","volume":"19","author":"Arab","year":"2020","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2025.101903","article-title":"Updated recommendations for the management of metabolic dysfunction\u2013associated steatotic liver disease (MASLD) by the Latin American working group","volume":"30","author":"Diaz","year":"2025","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0072","first-page":"69","article-title":"Consenso mexicano de la enfermedad por h\u00edgado graso no alcoh\u00f3lico","volume":"84","author":"Bernal-Reyes","year":"2019","journal-title":"Rev Gastroenterol M\u00e9x"},{"key":"10.1016\/j.arcmed.2026.103476_bib0073","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s13679-024-00585-w","article-title":"Mexican Clinical Practice Guidelines for Adult Overweight and Obesity Management","volume":"13","author":"Ch\u00e1vez-Manzanera","year":"2024","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.arcmed.2026.103476_bib0074","article-title":"Gu\u00eda mexicana de pr\u00e1ctica cl\u00ednica para el diagn\u00f3stico y tratamiento en pacientes adultos con diabetes tipo 2","volume":"10","author":"Secchi-Nicol\u00e1s","year":"2024","journal-title":"RME"},{"key":"10.1016\/j.arcmed.2026.103476_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2025.101935","article-title":"Hepatocellular carcinoma surveillance: Current challenges in Latin America","volume":"30","author":"Pages","year":"2025","journal-title":"Ann Hepatol"},{"issue":"Supl","key":"10.1016\/j.arcmed.2026.103476_bib0079","first-page":"1","article-title":"Gu\u00eda de pr\u00e1ctica cl\u00ednica mexicana para el diagn\u00f3stico y tratamiento de las dislipidemias y enfermedad cardiovascular ateroscler\u00f3tica","volume":"92","author":"Pav\u00eda-L\u00f3pez","year":"2022","journal-title":"Arch Cardiol Mex"},{"key":"10.1016\/j.arcmed.2026.103476_bib0080","first-page":"69","article-title":"The Mexican consensus on nonalcoholic fatty liver disease","volume":"84","author":"Bernal-Reyes","year":"2019","journal-title":"Rev Gastroenterol Mex (Engl)"},{"key":"10.1016\/j.arcmed.2026.103476_bib0081","unstructured":"Instituto Mexicano del Seguro Social Direcci\u00f3n de Prestaciones M\u00e9dicas. Tratamiento quir\u00fargico de la Obesidad m\u00f3rbida en el adulto. 2018. Available from: https:\/\/www.imss.gob.mx\/sites\/all\/statics\/guiasclinicas\/051GER.pdf. (Accessed February 16, 2026)."},{"key":"10.1016\/j.arcmed.2026.103476_bib0083","unstructured":"Subsecretar\u00eda de Prevenci\u00f3n y Promoci\u00f3n de la Salud, Centro Nacional de Programas Preventivos y Control de Enfermedades. Manual para la adopci\u00f3n de cl\u00ednicas de cirug\u00eda bariatrica. M\u00e9xico: Gobierno de M\u00e9xico;. Available from: https:\/\/www.gob.mx\/cms\/uploads\/attachment\/file\/416509\/Manual_Cl_nicas_de_Obesidad_editado__1_.pdf. (Accessed April 16, 2026)."},{"key":"10.1016\/j.arcmed.2026.103476_bib0084","unstructured":"Centro Nacional para la Prevenci\u00f3n y el Control del VIH y el Sida (CENSIDA). Programa de Acci\u00f3n Espec\u00edfico: prevenci\u00f3n, diagn\u00f3stico y tratamiento de la hepatitis C 2016-2018. M\u00e9xico: Secretar\u00eda de Salud; 2016. Available from: gob.mx. (Accessed April 16, 2026)."},{"key":"10.1016\/j.arcmed.2026.103476_bib0085","unstructured":"Instituto Mexicano del Seguro Social (IMSS). IMSS-719-14: Diagn\u00f3stico y tratamiento de la enfermedad hep\u00e1tica grasa no alcoh\u00f3lica del adulto. IMSS. Available from: chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/ https:\/\/www.imss.gob.mx\/sites\/all\/statics\/guiasclinicas\/719GER.pdf. (Accessed April 16, 2026)."},{"key":"10.1016\/j.arcmed.2026.103476_bib0086","unstructured":"Secretaria de Salud (SSA). Protocolo Nacional de Atenci\u00f3n M\u00e9dica: Sobrepeso y obesidad en adultos. M\u00e9xico: Consejo de Salubridad General; 2023. Available from: https:\/\/pronamsalud.csg.gob.mx\/pronam-sobrepeso-y-obesidad-adultos.pdf. (Accessed March 30, 2026)."},{"key":"10.1016\/j.arcmed.2026.103476_bib0087","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70390","article-title":"Cost of Metabolic Dysfunction-Associated Steatotic Liver Disease Screening Among All People Living With Diabetes in Six Countries","volume":"45","author":"Lazarus","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.arcmed.2026.103476_bib0088","unstructured":"World Obesity Federation. World Obesity Atlas 2025. London: World Obesity Federation; 2025. Available from: https:\/\/s3-eu-west-1.amazonaws.com\/wof-files\/World_Obesity_Atlas_2025_rev1.pdf. (Accessed March 25, 2026)."},{"key":"10.1016\/j.arcmed.2026.103476_bib0089","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.2147\/DMSO.S208884","article-title":"Lifestyle intervention for obesity: a call to transform the clinical care delivery system in Mexico","volume":"12","author":"D\u00edaz-Zavala","year":"2019","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.arcmed.2026.103476_bib0090","unstructured":"Global Burden of Disease Study 2023 (GBD 2023) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2024. Available at: https:\/\/vizhub.healthdata.org\/gbd-results\/; (Accessed March 10, 2026)."},{"key":"10.1016\/j.arcmed.2026.103476_bib0091","doi-asserted-by":"crossref","first-page":"725","DOI":"10.21149\/12842","article-title":"Prevalence of diabetes and glycemic control in Mexico: national results from 2018 and 2020","volume":"63","author":"Basto-Abreu","year":"2021","journal-title":"Salud Publica Mex"},{"key":"10.1016\/j.arcmed.2026.103476_bib0092","unstructured":"International Diabetes Federation. Diabetes Atlas 10th Edition. Available at: https:\/\/diabetesatlas.org\/data-by-location\/country\/mexico\/International Diabetes. (Accessed March 10, 2026)."},{"key":"10.1016\/j.arcmed.2026.103476_bib0093","series-title":"World Obesity Atlas 2025","year":"2025"},{"key":"10.1016\/j.arcmed.2026.103476_bib0095","unstructured":"License for Use of Current Procedural Terminology, Fourth Edition (\"CPT\u00ae\"). United States Government, Ministry of Health. https:\/\/www.cms.gov\/license\/ama?file=\/files\/zip\/24CLABQ2.zip. (Accessed March 10, 2026)."},{"key":"10.1016\/j.arcmed.2026.103476_bib0096","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jhep.2019.05.033","article-title":"Intelligent liver function testing (iLFT): A trial of automated diagnosis and staging of liver disease in primary care","volume":"71","author":"Dillon","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0097","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1097\/HEP.0000000000001121","article-title":"Disparities in screening and risk stratification for Hispanic adults with metabolic dysfunction-associated steatotic liver disease","volume":"81","author":"Tincopa","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.arcmed.2026.103476_bib0098","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/HEP.0000000000001058","article-title":"A narrative review of lifestyle management guidelines for metabolic dysfunction\u2013associated steatotic liver disease","volume":"83","author":"Ivancovsky Wajcman","year":"2024","journal-title":"Hepatol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0100","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2026.103476_bib0101","unstructured":"Rezdiffra (resmetirom): summary of product characteristics. Amsterdam: EMA: European Medicines Agency; 2025. Report No. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rezdiffra-epar-product-information_en.pdf. (Accessed March 18, 2026)."},{"key":"10.1016\/j.arcmed.2026.103476_bib0102","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction\u2013Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2026.103476_bib0103","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/HEP.0000000000001608","article-title":"Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance","volume":"83","author":"Bansal","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.arcmed.2026.103476_bib0104","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Summary of opinion: Kayshild (semaglutide). Amsterdam: European Medicines Agency (EMA); 2026. Report No.: EMA\/CHMP\/17332\/2026. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-kayshild_en.pdf. (Accessed March 30, 2026)."},{"key":"10.1016\/j.arcmed.2026.103476_bib0105","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.arcmed.2026.103476_bib0106","unstructured":"Organisation for Economic Co-operation and Development. Income inequality (Gini coefficient), Mexico. 2022. Available from: https:\/\/data-explorer.oecd.org\/vis?fs[0]=Topic%2C1%7CSociety%23SOC%23%7CInequality%23SOC_INE%23&pg=0&fc=Topic&bp=true&snb=2&df[ds]=dsDisseminateFinalDMZ&df[id]=DSD_WISE_IDD%40DF_IDD&df[ag]=OECD.WISE.INE&df[vs]=1.0&pd=2022%2C2024&dq=MEX.A.INC_DISP_GINI..._T.METH2012.D_CUR.&to[TIME_PERIOD]=false&vw=tb. (Accessed Apr 6, 2026)."},{"key":"10.1016\/j.arcmed.2026.103476_bib0107","doi-asserted-by":"crossref","unstructured":"OECD. Health at a Glance 2025: OECD Indicators. OECD Publishing; 2025. (Health at a Glance). Available from: https:\/\/www.oecd.org\/en\/publications\/health-at-a-glance-2025_8f9e3f98-en.html. https:\/\/doi.org\/10.1787\/8f9e3f98-en. (Accessed Apr 6, 2026).","DOI":"10.1787\/8f9e3f98-en"},{"key":"10.1016\/j.arcmed.2026.103476_bib0108","unstructured":"World Health Organization. UHC index of service coverage - Mexico (SDG 3.8.1). Universal Health Coverage Dataset; 2023. Available from: https:\/\/data.worldbank.org\/indicator\/SH_UHC_SCI?locations=MX. (Accessed Apr 6, 2026)."},{"key":"10.1016\/j.arcmed.2026.103476_bib0113","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12889-025-23481-x","article-title":"Food and beverage marketing directed at youth in 11 Latin American countries: a scoping review","volume":"26","author":"Mungu\u00eda","year":"2025","journal-title":"BMC Public Health"},{"key":"10.1016\/j.arcmed.2026.103476_bib0114","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3945\/jn.117.251892","article-title":"After Mexico Implemented a Tax, Purchases of Sugar-Sweetened Beverages Decreased and Water Increased: Difference by Place of Residence, Household Composition, and Income Level","volume":"147","author":"Colchero","year":"2017","journal-title":"J Nutr"},{"key":"10.1016\/j.arcmed.2026.103476_bib0115","doi-asserted-by":"crossref","DOI":"10.1136\/bmjph-2024-001524","article-title":"Changes in sugar-sweetened beverages and non-essential energy-dense food purchases overall and by type before and after the implementation of taxes in Mexico: repeated cross-sectional national surveys (2008\u20132018)","volume":"3","author":"Garc\u00eda-Ch\u00e1vez","year":"2025","journal-title":"bmjph"},{"key":"10.1016\/j.arcmed.2026.103476_bib0117","unstructured":"Tackling NCDs: best buys and other recommended interventions for the prevention and control of noncommunicable diseases. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"10.1016\/j.arcmed.2026.103476_bib0118","unstructured":"World Health Organization. Resolution WHA79.4: Strengthening action on metabolic dysfunction-associated steatotic liver disease (MASLD) and other steatotic liver diseases. Geneva: World Health Organization; 2026. Available from: https:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA79\/A79_R4-en.pdf. (Accessed Mar 30, 2026)."}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440926000986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440926000986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T19:57:33Z","timestamp":1785959853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440926000986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":102,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0188440926000986"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2026.103476","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addressing the Public Health Threat of Steatotic Liver Disease in Mexico","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2026.103476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103476"}}